Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis’ MoxDuo: Can A Generic Firm Drive Growth With A Low-Dose Product?

Executive Summary

Actavis aims to replace its Kadian pain franchise through a deal with QRxPharma for a fixed-dose combination of morphine and oxycodone.

You may also be interested in...



QRxPharma’s Dual-Opioid Therapy MoxDuo Will Face FDA Cmte. Scrutiny

FDA told the company there is no precedent for reviewing a combination product that contains two drugs from the same class. The company’s NDA resubmission for the morphine/oxycodone immediate-release product will include oxygen saturation data from a study originally conducted for European regulators.

Pain Prescriber Education Programs Need Better Coordination, GAO Says

FDA and other federal agencies could better coordinate their efforts to educate prescribers about prescription pain reliever abuse, the Government Accountability Office said.

FDA Restrictions On Rx Acetaminophen Show How Practical Concerns Influence Safety Actions

Because the agency can move faster on Rx products than OTCs, non-prescription products will have higher acetaminophen levels than Rx drugs, at least for the time being.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel